EE470 The Impact of a Cost Savings Cap on the Cost Effectiveness of Valoctocogene Roxaparvovec for the Treatment of Hemophilia A in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.2235
https://www.valueinhealthjournal.com/article/S1098-3015(24)02449-5/fulltext
Title :
EE470 The Impact of a Cost Savings Cap on the Cost Effectiveness of Valoctocogene Roxaparvovec for the Treatment of Hemophilia A in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)02449-5&doi=10.1016/j.jval.2024.03.2235
First page :
Section Title :
Open access? :
No
Section Order :
10232